Two for good measure: Six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer

Gynecologic Oncology

Volumn 100, Issue 2, 2006, Pages 417-421

  Dizon, Don S ^a,b   Weitzen, Sherry ^b   Rojan, Adam ^b   Schwartz, Joanna ^a   Miller, Jane ^a   DiSilvestro, Paul ^a,b   Gordinier, Mary E ^a,b   Moore, Richard ^a,b   Tejada Berges, Trevor ^a,b   Pires, Leslie ^a   Legare, Robert ^a,b   Granai, Cornelius O ^a,b  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Chemotherapy; Ovarian cancer; Survival outcomes

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES;

EID: 30444434411     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.10.031     Document Type: Article

References (20)

1. A. Jemal, R.C. Tiwari, and T. Murray Cancer statistics, 2004 CA Cancer J. Clin. 54 2004 8 29
2. L.A.G. Ries M.P. Eisner C.L. Kosary SEER Cancer Statistics Review 1975-2002 National Cancer Institute Bethesda
3. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
4. M.J. Piccart, K. Bertelsen, and K. James Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J. Natl. Cancer Inst. 92 2000 699 708
5. M.J. Piccart, K. Bertelsen, and G. Stuart Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer Int. J. Gynecol. Cancer 13 Suppl 2 2003 144 148
6. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 21 2003 3194 3200
7. A. du Bois, H.J. Luck, and W. Meier A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J. Natl. Cancer Inst. 95 2003 1320 1329
8. T.B. Hakes, E. Chalas, and W.J. Hoskins Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma Gynecol. Oncol. 45 1992 284 289
9. D.M. Gershenson, M.F. Mitchell, and N. Atkinson The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered Gynecol. Oncol. 47 1992 7 13
10. K. Bertelsen, A. Jakobsen, and J. Stroyer A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA) Gynecol. Oncol. 49 1993 30 36
11. H.E. Lambert, G.J. Rustin, and W.M. Gregory A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study Ann. Oncol. 8 1997 327 333
12. H.E. Lambert, G.J. Rustin, and W.M. Gregory A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: A North Thames Ovary Group study J. Clin. Oncol. 11 1993 440 448
13. M. Markman, P.Y. Liu, and S. Wilczynski Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial J. Clin. Oncol. 21 2003 2460 2465
14. G.J. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J. Clin. Oncol. 21 2003 187 193
15. N. Einhorn, K. Sjovall, and R.C. Knapp Prospective evaluation of serum CA 125 levels for early detectomy of ovarian cancer Obstet. Gynecol. 80 1992 14 18
16. W.J. Hoskins, W.P. McGuire, and M.F. Brady The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am. J. Obstet. Gynecol. 170 1994 974 979 [Discussion 979-80]
17. J.R. Redman, G.R. Petroni, and P.E. Saigo Prognostic factors in advanced ovarian carcinoma J. Clin. Oncol. 4 1986 515 523
18. G.J. Rustin, A.E. Nelstrop, and P. McClean Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 J. Clin. Oncol. 14 1996 1545 1551
19. B. Gronlund, C. Hogdall, and J. Hilden Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J. Clin. Oncol. 22 2004 4051 4058
20. G.J. Rustin, M. Quinn, and J.T. Thigpen RE: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) J. Natl. Cancer Inst. 96 2004 487 488